LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 30, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will
report its first quarter 2015 financial results on Thursday, May 7,
2015, before market open.
Following the announcement, management will host a conference call and
webcast at 10:00 a.m. ET that morning to discuss the first quarter
results and provide operational updates.
The conference call can be accessed by dialing (877) 407-8035 (U.S.) or
(201) 689-8035 (International). For those unable to join the live call,
a replay will be available from 2:00 p.m. ET on May 7 through 11:59 p.m.
ET on May 14. To access the replay, please dial (877) 660-6853 (U.S.) or
(201) 612-7415 (International) and refer to conference ID 13607924.
The live webcast
can be accessed by visiting the Investor
Relations section of the Synta Pharmaceuticals website, www.syntapharma.com.
The webcast will also be archived under Webcasts
and Events within the Investor Relations section of the Company's
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical
company focused on research, development and commercialization of novel
oncology medicines that have the potential to change the lives of cancer
patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat
shock protein 90 (Hsp90) inhibitor, is currently being evaluated in
several clinical trials including the pivotal GALAXY-2 Phase 3 trial in
non-small cell lung cancer. Building on its extensive expertise in the
science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor
Drug Conjugate (HDC) small molecule drug development program. IND
enabling studies have commenced for the first clinical candidate from
the HDC program, STA-12-8666, and preclinical evaluation of additional
HDC candidates is ongoing. For more information, please visit www.syntapharma.com.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Daniel Cole, 781-541-7250
Andrea Rabney, 212-600-1494
Eliza Schleifstein, 917-763-8106